The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Janssen and Johnson & Johnson to Present Latest Phase 3 Results for Canagliflozin in the Treatment of Patients with Type 2 Diabetes

Wednesday, September 26, 2012

Janssen and Johnson & Johnson to Present Latest Phase 3 Results for Canagliflozin in the Treatment of Patients with Type 2 Diabetes09:18 EDT Wednesday, September 26, 2012NEW BRUNSWICK, N.J., Sept. 26, 2012 /PRNewswire-FirstCall/ -- Janssen Research & Development, LLC and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Tuesday, October 2, at approximately 12:00 p.m., Eastern Time, to coincide with the 48th European Association for the Study of Diabetes (EASD) Annual Meeting in Berlin, Germany. First results from the ongoing phase 3 CANVAS trial evaluating canagliflozin in patients with type 2 diabetes at elevated risk for cardiovascular disease will be shown at EASD.  Additionally, data from DIA3010, which evaluated canagliflozin as add-on therapy in patients aged 55 to 80, on antihyperglycemic therapy without adequate glycemic control, will be presented.A pre-recorded webcast with Kirk Ways, M.D., Ph.D, Vice President and compound development team leader for canagliflozin from Janssen Research & Development, will provide an update on the CANVAS sub-study and DIA3010 results. The webcast/podcast can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on "Webcasts/Presentations."SOURCE Johnson & JohnsonFor further information: Press Contacts: Al Wasilewski, +1-(732) 524-1130, or Bill Price, +1-(732) 524-6623, or Investor Contacts: Stan Panasewicz, +1-(732) 524-2524, or Louise Mehrotra, +1-(732) 524-6491